Bristol Myers Squibb (BMY)

[DewDiligence]

BMY 4Q19 results/2020-2021 guidance:

https://investors.bms.com/iframes/press-releases/press-release-details/2020/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2019/default.aspx

2020 non-GAAP EPS guidance is $6.00-6.20, and 2021 non-GAAP-EPS guidance is $7.15-7.45. (2019 actual non-GAAP EPS of $4.69 is not directly comparable because it included CELG for only two months.).

2020 revenue guidance is $40.5-42.5B. (2019 actual revenue of $26.1B is not directly comparable because it included CELG for only two months.) There is no revenue guidance for 2021.

BMY authorized a new $5B share-buyback, and there is ~$1B remaining on the existing buyback authorization.